Publications by authors named "X T Deng"

Objectives: We aimed to: (1) explore the effect of oral potassium supplementation on urinary potassium excretion, and (2) evaluate the value of urinary potassium-related indicators in distinguishing primary aldosteronism (PA) from non-PA patients.

Design And Methods: A prospective study of 20 patients with hypertension and hypokalemia caused by renal potassium loss between November 2023 and April 2024 was conducted. Demographic features, 24-hour urine collection before and after potassium supplementation were all collected.

View Article and Find Full Text PDF

This paper reviews recent developments and key advances in terahertz (THz) science, technology, and applications, focusing on 3 core areas: astronomy, telecommunications, and biophysics. In THz astronomy, it highlights major discoveries and ongoing projects, emphasizing the role of advanced superconducting technologies, including superconductor-insulator-superconductor (SIS) mixers, hot electron boundedness spectroscopy (HEB), transition-edge sensors (TESs), and kinetic inductance detectors (KIDs), while exploring prospects in the field. For THz telecommunication, it discusses progress in solid-state sources, new communication technologies operating within the THz band, and diverse modulation methods that enhance transmission capabilities.

View Article and Find Full Text PDF

Purpose: To develop and validate a radiomics nomogram model for predicting the micropapillary pattern (MPP) in lung adenocarcinoma (LUAD) tumors of ≤2 cm in size.

Methods: In this study, 300 LUAD patients from our institution were randomly divided into the training cohort (n = 210) and an internal validation cohort (n = 90) at a ratio of 7:3, besides, we selected 65 patients from another hospital as the external validation cohort. The region of interest of the tumor was delineated on the computed tomography (CT) images, and radiomics features were extracted.

View Article and Find Full Text PDF

To overcome the compensatory effect between Topo I and II, one of the reasons accounting for the resistance of SCLC patients, we are pioneering the use of 3-arylisoquinolines to develop dual inhibitors of Topo I/II for the management of SCLC. A total of 46 new compounds were synthesized. Compounds (IC = 1.

View Article and Find Full Text PDF